Projects

Venture Leaders Medtech: Two Wyss Zurich projects among selected 10

project MYNERVA and Apersys AG were recently selected to join the Venture Leaders Medtech 2024. They will travel with 8 other leaders to Boston from 4 to 6 November 2024.

During the one-week roadshow, the 10 Venture Leaders will meet investors in the US and engage with executives and experts in the Medtech industry.

Boston is one of the world’s major life sciences hubs and the ideal springboard for ambitious startups on their way to global expansion. By building a strong network, entrepreneurs will be able to accelerate their international growth.

This article first appeared on Venturelab.

Read more

Recommended News

Annual Event 10 Years Wyss Zurich

Wyss Zurich celebrated its 10th anniversary at the Annual Event on November 3rd 2025. Over 300 guests gathered at the Kongresshaus Zurich to celebrate 10 years of impact by the Wyss Zurich Translational Center.

MYNERVA wins the Diamond Prize of MassChallange 2025

MassChallenge Switzerland, part of MassChallenge’s global network for innovators and zero-equity startup accelerators, yesterday hosted its 10th Anniversary Awards Ceremony in Lausanne, Switzerland.

Turning Ideas into Impact — Tethys Robotics raises Eur 3.5M

Wyss Zurich congratulates Tethys Robotics on raising €3.5 million to expand its autonomous underwater robot, Tethys ONE — advancing safety-critical missions from offshore energy to search and rescue.
Scion Day

Bridging Innovation and Implementation: Remote Robotic Surgery and the Future of Secure Connectivity

Wyss Zurich celebrates its alumni Nanoflex Robotics for contributing to the discussion on the future of remote robotic surgery. At SCION Day 2025, experts explored how 5G and SCION networks can enable safe, real-time surgical interventions.
MYNERVA News

Smart socks that alleviate pain

Diabetes leads to nerve damage in half of all people affected, starting in the feet. The smart sock from ETH spin-off MYNERVA helps sufferers feel the ground again when walking and alleviates their chronic pain.

Interview: Dr. Ana Montalban-Arques on Adularia’s Strategic Transition to Molecular Cancer Treatments

A lot changes in the first few years of a startup. This was also the case at Adularia, formerly Recolony: a discovery in the laboratory led to a new focus, which resulted in the repositioning of the entire company.

Sign up for our newsletter!

For newsletter distribution, your email address will be processed by a GDPR-certified service provider. Further information can be found in our privacy policy.